Sponsors Announced for CHI's Accelerating Proof of Concept Conference in Philadelphia

Aug. 25, 2011 - PRLog -- Biovista, Cetero Research, and Lotus Clinical Research, LLC, are confirmed as sponsors of CHI's third annual Accelerating-Proof-of-Concept: Clinical Success Driven by Science & Strategy conference.  This conference will take place on October 3-5, 2011 at the Crowne Plaza Philadelphia Downtown, Philadelphia, PA. These companies will present on the following days and times:

CETERO RESEARCH - Monday, October 3, 4:30-5:00 p.m.

The Living Document: Developing an Accelerated Proof-of-Concept
Alan Copa, Pharm.D., President, Clinical Operations, Fargo, Cetero Research

This session focuses on how-to’s for developing a robust, yet flexible protocol to accommodate up to four different studies. Topics covered include: Regulatory and ethical concerns, Inclusion/exclusion criteria, Dose flexibility, Stopping points, Timing and logistics of overlapping cohorts, Safety reviews

BIOVISTA - Tuesday, October 4, 12:00-12:30 p.m.

How Systematic Indication Expansion can Accelerate Proof of Concept
Aris Persidis, Ph.D., President & CoFounder, Biovista

Methods and technologies that can reduce the time it takes for an advanced drug candidate to enter the clinic and provide an efficacy signal are widely needed. Using mechanism of action to systematically explore potential efficacy/risk scenarios for a drug helps accelerate development towards Phase IIa and proof of concept/mechanism trials. Biovista's Clinical Outcome Search Space Technology maps all drugs against all 23,000 indications and 6,000 adverse events tracked by medicine and is used to accelerate proof of concept. Case studies will be discussed on MS, epilepsy and oncology.

LOTUS CLINICAL RESEARCH, LLC - Tuesday, October 3, 3:05-3:35 p.m.

Evaluating Clinical Research Sites, Let’s Get Scientific about Data Quality
Neil K. Singla, M.D., CEO, Lotus Clinical Research, LLC

When speaking about data quality, most sponsors focus on data cleanliness and not data accuracy. Data cleanliness has to do with appropriate recording and transcription of data with the avoidance of queries. Data accuracy is much more important! Did the site reveal the treatment effect that the study was designed to show? By using a simple metric, the standardized effect size, the contribution of individual centers toward or away from the primary endpoint can be evaluated.

For more information and to register, please visit http://www.healthtech.com/pfc. Those that register by August 26 will save up to $200.

To inquire about sponsoring and/or exhibiting, contact Carol Dinerstein, 781-972-5471, dinerstein@healthtech.com.

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com